S-adenosylmethionine (SAM) is an important metabolite as a methyl-group donor in DNA and histone methylation, tuning regulation of gene expression. Appropriate intracellular SAM levels must be maintained, because methyltransferase reaction rates can be limited by SAM availability. In response to SAM depletion, MAT2A, which encodes a ubiquitous mammalian methionine adenosyltransferase isozyme, was upregulated through mRNA stabilization. SAM-depletion reduced N-methyladenosine (mA) in the 3' UTR of MAT2A. In vitro reactions using recombinant METTL16 revealed multiple, conserved methylation targets in the 3' UTR. Knockdown of METTL16 and the mA reader YTHDC1 abolished SAM-responsive regulation of MAT2A. Mutations of the target adenine sites of METTL16 within the 3' UTR revealed that these mAs were redundantly required for regulation. MAT2A mRNA methylation by METTL16 is read by YTHDC1, and we suggest that this allows cells to monitor and maintain intracellular SAM levels.
Edited by Joel M. GottesfeldFerroptosis is an iron-dependent programmed cell death event, whose regulation and physiological significance remain to be elucidated. Analyzing transcriptional responses of mouse embryonic fibroblasts exposed to the ferroptosis inducer erastin, here we found that a set of genes related to oxidative stress protection is induced upon ferroptosis. We considered that up-regulation of these genes attenuates ferroptosis induction and found that the transcription factor BTB domain and CNC homolog 1 (BACH1), a regulator in heme and iron metabolism, promotes ferroptosis by repressing the transcription of a subset of the erastin-induced protective genes. We noted that these genes are involved in the synthesis of GSH or metabolism of intracellular labile iron and include glutamate-cysteine ligase modifier subunit (Gclm), solute carrier family 7 member 11 (Slc7a11), ferritin heavy chain 1 (Fth1), ferritin light chain 1 (Ftl1), and solute carrier family 40 member 1 (Slc40a1). Ferroptosis has also been previously shown to induce cardiomyopathy, and here we observed that Bach1 ؊/؊ mice are more resistant to myocardial infarction than WT mice and that the severity of ischemic injury is decreased by the iron-chelator deferasirox, which suppressed ferroptosis. Our findings suggest that BACH1 represses genes that combat labile iron-induced oxidative stress, and ferroptosis is stimulated at the transcriptional level by BACH1 upon disruption of the balance between the transcriptional induction of protective genes and accumulation of iron-mediated damage. We propose that BACH1 controls the threshold of ferroptosis induction and may represent a therapeutic target for alleviating ferroptosisrelated diseases, including myocardial infarction. This work was supported in part by Grants-in-Aid from the Japan Society for the Promotion of Science 19K07680 and 16K07108 (to M. M.) and 15H02506, 24390066, 21249014, and 18H04021 (to K. I.) and Agency for Medical Research and Development Grant JP16gm050001 (to K. I.). H. Nishizawa received DFX as raw material from Novartis Pharma for this study. The authors declare that they have no conflicts of interest with the contents of this article. This article contains Figs. S1-S10, Tables S1-S3, and Movie S1 The RNA-seq data has been deposited at the GEO database under accession code GSE131444.
Pancreatic ductal adenocarcinoma (PDAC) is among the cancers with the poorest prognoses due to its highly malignant features. BTB and CNC homology 1 (BACH1) has been implicated in RAS-driven tumor formation. We focused on the role of BACH1 in PDAC, more than 90% of which have KRAS mutation. Knockdown of BACH1 in PDAC cell lines reduced cell migration and invasion, in part, by increasing E-cadherin expression, whereas its overexpression showed opposite effects. BACH1 directly repressed the expression of FOXA1 that is known to activate the expression of CDH1 encoding E-cadherin and to inhibit epithelial-to-mesenchymal transition. BACH1 also directly repressed the expression of genes important for epithelial cell adhesion including CLDN3 and CLDN4. In a mouse orthotopic implantation model, BACH1 was required for the high metastatic ability of AsPC-1 cells. IHC analysis of clinical specimens with a newly developed anti-BACH1 mAb revealed that high expression of BACH1 is a poor prognostic factor. These results suggest that the gene regulatory network of BACH1 and downstream genes including CDH1 contribute to the malignant features of PDAC by regulating epithelial-tomesenchymal transition.Significance: Greater understanding of the gene regulatory network involved in epithelial-to-mesenchymal transition of pancreatic cancer cells will provide novel therapeutic targets and diagnostic markers.
Primordial germ cells (PGCs), undifferentiated embryonic germ cells, are the only cells that have the ability to become gametes and to reacquire totipotency upon fertilization. It is generally understood that the development of PGCs proceeds through the expression of germ cell-specific transcription factors and characteristic epigenomic changes. However, little is known about the properties of PGCs at the metabolite and protein levels, which are directly responsible for the control of cell function. Here, we report the distinct energy metabolism of PGCs compared with that of embryonic stem cells. Specifically, we observed remarkably enhanced oxidative phosphorylation (OXPHOS) and decreased glycolysis in embryonic day 13.5 (E13.5) PGCs, a pattern that was gradually established during PGC differentiation. We also demonstrate that glycolysis and OXPHOS are important for the control of PGC reprogramming and specification of pluripotent stem cells (PSCs) into PGCs in culture. Our findings about the unique metabolic property of PGCs provide insights into our understanding of the importance of distinct facets of energy metabolism for switching PGC and PSC status.primordial germ cell | metabolome | proteome | glycolysis | oxidative phosphorylation I n mouse, germ cells first develop as primordial germ cells (PGCs) from a subset of cells in late epiblasts consisting of primed pluripotent stem cells (PSCs) that differentiate from naïve PSCs, designated primitive ectoderm or early epiblast, at around embryonic day 7.25 (E7.25) in the extraembryonic mesoderm (1). Several cytokines (2) and transcription factors (3-5) have critical roles in the emergence of PGCs. Following their initial appearance, PGCs migrate and colonize the genital ridges at ∼E10.5, subsequently exhibiting sexual differentiation at ∼E11.5. After their initial development, PGCs undergo characteristic epigenetic reprogramming, including the global reduction of histone H3 lysine 9 dimethylation (H3K9me2) and DNA methylation (6-8). As a result of the dynamic changes in gene regulation and epigenetic states that occur in the course of PGC differentiation, PGCs have developmental potential distinct from that of PSCs. Notably, PGCs show dormant totipotency, although PGCs are monopotential cells for the generation of gametes. Nonetheless, PGCs and PSCs remain closely related: both cell types share the expression of several pluripotency-associated transcription factors (9-12), and PGCs are easily reprogrammed into naïve PSCs, designated embryonic germ cells (EGCs), in culture (13,14). Therefore, the intrinsic mechanisms that control the distinct developmental potential of these two cell types are of great interest.Recent studies have focused primarily on the transcriptome and epigenome to explain the functional difference between PSCs and PGCs. However, the differences in metabolites and proteins in these cells, which may be closely linked to their distinct developmental potential, have not been examined. Recently, exhaustive analyses of metabolites, especially re...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.